Suppr超能文献

蛋白酶:丝氨酸蛋白酶抑制剂复合物用于评估接触系统和内源性途径激活。

Protease: Serpin complexes to assess contact system and intrinsic pathway activation.

作者信息

Henderson Michael W, Noubouossie Denis F, Ilich Anton, Wilson Kathy J, Pawlinski Rafal, Monroe Dougald M, Key Nigel S

机构信息

Department of Pathology and Laboratory Medicine University of North Carolina at Chapel Hill Chapel Hill NC USA.

UNC Blood Research Center University of North Carolina at Chapel Hill Chapel Hill NC USA.

出版信息

Res Pract Thromb Haemost. 2020 Jun 25;4(5):789-798. doi: 10.1002/rth2.12389. eCollection 2020 Jul.

Abstract

Mounting evidence suggests that a variety of disease states are pathophysiologically related to activation of the contact system in vivo. The plasma contact system is composed of a cascade of serine proteases initiated by surface activation of factor XII, which can then proceed through a procoagulant pathway by activating the intrinsic coagulation factor XI, or a proinflammatory pathway by activating prekallikrein. Serpins are the primary endogenous inhibitors of the contact system, which irreversibly inhibit their respective protease(s), forming a stable complex. We modified an existing assay strategy for detecting these complexes in plasma using ELISAs and determined the effect of preanalytical variation caused by anticoagulant selection and processing time. The assays were sensitive and specific to inherited deficiency of individual contact factors. We conclude that these assays are robust and represent a relatively simple approach to the assessment of contact factor activation in plasma samples.

摘要

越来越多的证据表明,多种疾病状态在病理生理学上与体内接触系统的激活有关。血浆接触系统由一系列丝氨酸蛋白酶组成,这些蛋白酶由因子XII的表面激活引发,然后可以通过激活内源性凝血因子XI进入促凝途径,或者通过激活前激肽释放酶进入促炎途径。丝氨酸蛋白酶抑制剂(Serpins)是接触系统的主要内源性抑制剂,它们不可逆地抑制各自的蛋白酶,形成稳定的复合物。我们改进了一种现有的检测血浆中这些复合物的检测策略,采用酶联免疫吸附测定(ELISA),并确定了抗凝剂选择和处理时间引起的分析前变异的影响。这些检测方法对个体接触因子的遗传性缺乏敏感且特异。我们得出结论,这些检测方法是可靠的,并且是评估血浆样本中接触因子激活的一种相对简单的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b851/7354413/bc6165947b1f/RTH2-4-789-g001.jpg

相似文献

1
Protease: Serpin complexes to assess contact system and intrinsic pathway activation.
Res Pract Thromb Haemost. 2020 Jun 25;4(5):789-798. doi: 10.1002/rth2.12389. eCollection 2020 Jul.
2
The plasma contact system, a protease cascade at the nexus of inflammation, coagulation and immunity.
Biochim Biophys Acta Mol Cell Res. 2017 Nov;1864(11 Pt B):2118-2127. doi: 10.1016/j.bbamcr.2017.07.009. Epub 2017 Jul 23.
4
Formation of bradykinin: a major contributor to the innate inflammatory response.
Adv Immunol. 2005;86:159-208. doi: 10.1016/S0065-2776(04)86005-X.
5
Proteolytic activity of contact factor zymogens.
J Thromb Haemost. 2021 Feb;19(2):330-341. doi: 10.1111/jth.15149. Epub 2020 Dec 7.
8
Anticoagulant SERPINs: Endogenous Regulators of Hemostasis and Thrombosis.
Front Cardiovasc Med. 2022 May 3;9:878199. doi: 10.3389/fcvm.2022.878199. eCollection 2022.
9
A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release.
J Thromb Haemost. 2017 Sep;15(9):1807-1817. doi: 10.1111/jth.13760. Epub 2017 Aug 2.
10
Glycated albumin modulates the contact system with implications for the kallikrein-kinin and intrinsic coagulation systems.
J Thromb Haemost. 2023 Apr;21(4):814-827. doi: 10.1016/j.jtha.2022.12.015. Epub 2022 Dec 27.

引用本文的文献

1
A novel factor IXa-specific enzyme-linked immunosorbent assay detects factor IXa in human plasma.
Res Pract Thromb Haemost. 2024 Feb 5;8(1):102338. doi: 10.1016/j.rpth.2024.102338. eCollection 2024 Jan.
2
Factor XII contributes to thrombotic complications and vaso-occlusion in sickle cell disease.
Blood. 2023 Apr 13;141(15):1871-1883. doi: 10.1182/blood.2022017074.
3
Contact and intrinsic coagulation pathways are activated and associated with adverse clinical outcomes in COVID-19.
Blood Adv. 2022 Jun 14;6(11):3367-3377. doi: 10.1182/bloodadvances.2021006620.

本文引用的文献

3
Hereditary angioedema: the plasma contact system out of control.
J Thromb Haemost. 2018 Sep;16(9):1674-1685. doi: 10.1111/jth.14209. Epub 2018 Jul 17.
4
Coagulation factor XII in thrombosis and inflammation.
Blood. 2018 Apr 26;131(17):1903-1909. doi: 10.1182/blood-2017-04-569111. Epub 2018 Feb 26.
5
Cleaved kininogen as a biomarker for bradykinin release in hereditary angioedema.
J Allergy Clin Immunol. 2017 Dec;140(6):1700-1703.e8. doi: 10.1016/j.jaci.2017.07.012. Epub 2017 Aug 4.
6
Factor XI as a Therapeutic Target.
Arterioscler Thromb Vasc Biol. 2016 Jul;36(7):1316-22. doi: 10.1161/ATVBAHA.116.306925. Epub 2016 May 12.
7
A nanobody-based method for tracking factor XII activation in plasma.
Thromb Haemost. 2013 Sep;110(3):458-68. doi: 10.1160/TH12-11-0792. Epub 2013 Jan 24.
10
Factor XIa and tissue factor activity in patients with coronary artery disease.
Thromb Haemost. 2008 Jan;99(1):142-9. doi: 10.1160/TH07-08-0499.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验